Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jihao Zhou

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Molecular Medicine Reports|September 5, 2013
The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivoJihao Zhou, Yonghui Li, Yushi Yao, et al.
Frontiers in Oncology|February 13, 2026
Safety and feasibility assessment of implantable chest wall venous access port for patients with acute leukemiaPeng Ke, Min Liao, Fan He, et al.
Frontiers in Oncology|February 28, 2022
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNSJihao Zhou, Min Zuo, Lifeng Li, et al.
Annals of Hematology|April 22, 2021
The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimenPeng Ke, Xinyou Zhang, Songbai Liu, et al.
Cell Transplantation|December 16, 2025
Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugsJiangtao Li, Wenxuan Huo, Yang Yang, et al.
Journal for Immunotherapy of Cancer|July 4, 2024
Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatinLiuhai Zheng, Huifang Wang, Jihao Zhou, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 12, 2024
LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical TrialsSue Ellen Cox, Joely Kaufman-Janette, Joel L Cohen, et al.
Leukemia & Lymphoma|April 24, 2026
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphomaLina Hu, Bo Lu, Xiaolei Wei, et al.
Analytica Chimica Acta|June 26, 2021
Combinatory strategy using nanoscale proteomics and machine learning for T cell subtyping in peripheral blood of single multiple myeloma patientsXueting Ye, Yun Yang, Jihao Zhou, et al.
Hematology (Amsterdam, Netherlands)|April 12, 2022
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphomaLihong Zhang, Haifei Yang, Chongsheng Qian, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Molecular Medicine Reports|September 5, 2013
The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivoJihao Zhou, Yonghui Li, Yushi Yao, et al.
Frontiers in Oncology|February 13, 2026
Safety and feasibility assessment of implantable chest wall venous access port for patients with acute leukemiaPeng Ke, Min Liao, Fan He, et al.
Frontiers in Oncology|February 28, 2022
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNSJihao Zhou, Min Zuo, Lifeng Li, et al.
Annals of Hematology|April 22, 2021
The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimenPeng Ke, Xinyou Zhang, Songbai Liu, et al.
Cell Transplantation|December 16, 2025
Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugsJiangtao Li, Wenxuan Huo, Yang Yang, et al.
Journal for Immunotherapy of Cancer|July 4, 2024
Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatinLiuhai Zheng, Huifang Wang, Jihao Zhou, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 12, 2024
LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical TrialsSue Ellen Cox, Joely Kaufman-Janette, Joel L Cohen, et al.
Leukemia & Lymphoma|April 24, 2026
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphomaLina Hu, Bo Lu, Xiaolei Wei, et al.
Analytica Chimica Acta|June 26, 2021
Combinatory strategy using nanoscale proteomics and machine learning for T cell subtyping in peripheral blood of single multiple myeloma patientsXueting Ye, Yun Yang, Jihao Zhou, et al.
Hematology (Amsterdam, Netherlands)|April 12, 2022
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphomaLihong Zhang, Haifei Yang, Chongsheng Qian, et al.
Pageof 5